• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Hydros Adoption Change PROCEPT BioRobotics Stock Narrative

    Simply Wall St·11/06/2026 17:20:35
    Listen to the news
    • PROCEPT BioRobotics reported Q3 2026 revenue of US$98.3 million and a net loss of US$26.5 million, while reiterating full year 2026 revenue guidance of US$390 million to US$410 million and indicating a target for positive adjusted EBITDA in Q4.
    • The business relied heavily on Hydros adoption, with higher procedure volumes and consumable usage at these accounts acting as a key driver of third quarter performance and the reaffirmed outlook.
    • We will look at how PROCEPT BioRobotics' investment narrative aligns with reaffirmed 2026 guidance and Hydros driven procedure momentum.

    Scan beyond PROCEPT BioRobotics and see how other robotics focused healthcare stocks with procedure driven momentum stack up inside the hand picked 89 robotics and automation stocks list.

    PROCEPT BioRobotics Investment Narrative Recap

    To own PROCEPT BioRobotics, an investor needs to believe Hydros led Aquablation can keep gaining traction, and that higher procedure volumes eventually cover a still heavy cost base. The Q3 2026 update showed revenue of US$98.3 million alongside a net loss of US$26.5 million, so the profitability story is not resolved yet.

    The most important near term catalyst is management’s goal for positive adjusted EBITDA in Q4 2026. That target depends on Hydros utilization, pricing discipline and expense control holding together. Rising losses over the first nine months to US$85.0 million keep execution risk around costs very real.

    The most relevant announcement tied to this update is the reiterated 2026 revenue outlook of US$390 million to US$410 million, with management also pointing to a Q4 adjusted EBITDA inflection. That guidance sits against nine month sales of US$275.9 million and reflects management’s stated confidence in procedure momentum and Hydros adoption.

    For investors, the key question is whether that guidance range and the EBITDA goal still feel achievable after a wider quarterly loss of US$0.46 per share and ongoing operating losses. Progress on the WATER IV prostate cancer trial and broader Aquablation use remains important over the longer term, but the near term test is delivering that Q4 profitability milestone without softening utilization trends.

    PROCEPT BioRobotics' current analyst narrative points to forecast revenues of US$593.3 million and earnings of US$75.0 million by 2029, based on 20.7% yearly revenue growth and an earnings improvement of about US$184.8 million from current earnings, compared with a US$109.8 million loss today.

    Discover why PROCEPT BioRobotics' fair value suggests a 10% potential upside to its current price before the market closes that gap.

    NasdaqGM:PRCT 1-Year Stock Price Chart
    NasdaqGM:PRCT 1-Year Stock Price Chart

    Exploring Other Perspectives

    The biggest swing factor the more bearish analysts focus on is slower Aquablation procedure conversion. Before this Q3 update, the lowest group had been pencilling in revenue of about US$583.4 million and earnings of roughly US$73.4 million by 2029, yet still argued PROCEPT BioRobotics merited only a US$16.0 target. That shows how widely views can differ. Use this quarter’s numbers as a prompt to compare those cautious assumptions with your own.

    Explore 6 other PROCEPT BioRobotics fair value estimates, including one that suggests as much as 21% downside from the current price.

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis.

    Looking For More Investment Ideas Beyond PROCEPT BioRobotics?

    If the PROCEPT BioRobotics story has sharpened your thinking, use that momentum to widen your opportunity set. A focused stock list can help you compare quality, risk and income potential quickly, instead of scrolling through tickers at random.

    • For investors who want potential upside without ignoring balance sheet strength, consider starting with a 42 high quality undervalued stocks that already screen well on both quality and valuation.
    • If resilience and capital preservation matter most to you, use a 32 resilient stocks with low risk scores to zero in on companies with more measured risk profiles.
    • Income focused investors who care about consistency as much as yield can review a 6 dividend fortresses that filters for higher payouts with supporting fundamentals.